InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 Tel Aviv, Israel, and Miami, Florida

Announces Abstract of 30-Day Results from the

U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

Aviv, Israel, and Miami, Florida - August 31, 2023 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard

Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results

from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional

Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas.

Slosman, chief executive officer of InspireMD, stated, "We are very pleased that an abstract detailing our 30-day follow-up data

from our C-Guardians IDE trial has been accepted for presentation at this year's VIVA conference, which is among the most important

gatherings of endovascular specialists each year. We believe CGuard EPS, with its novel MiroNet technology, offers next-level

neuroprotection that translates into superior short- and long-term patient outcomes, something we aim to demonstrate with this important

trial. We also look forward to sharing one-year data from C-Guardians in the second half of next year that, if positive, may support

a Premarket Approval Application (PMA) and allow us to potentially launch the CGuard Prime EPS stent system in the U.S. in the first

C-Guardians clinical trial is evaluating the safety and efficacy of the CGuard Carotid Stent System for the treatment of carotid

artery stenosis. The study, which completed enrollment in June 2023, enrolled 316 patients across 25 trial sites in the U.S. and Europe.

trial includes both symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS). The primary endpoint includes the

composite of the following: incidence of the following major adverse events: death (all- cause mortality), all stroke, and myocardial

infarction (DSMI) through 30-days post-index procedure, based on the Clinical Events Committee (CEC) adjudication or ipsilateral stroke

from 31-365-day follow-up, based on CEC adjudication. The performance goal will be considered to have been met if the upper bound of

the two-sided 95% confidence interval calculated from the observed primary endpoint rate is <11.6% and the p-value is <0.025.

company anticipates primary endpoint results from the study in H2 2024.

(Vascular InterVentional Advances) is a global educational event for specialists caring for patients with vascular disease. VIVA brings

together attendees and faculty specializing in vascular surgery, interventional cardiology, interventional radiology, vascular medicine,

neurointervention/neurosurgery, and cardiothoracic surgery, offering a uniquely comprehensive educational experience with access to some

of the best minds in endovascular care.

seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing

outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the

routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements

regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such

statements may be preceded by the words "intends," "may," "will," "plans," "expects,"

"anticipates," "projects," "predicts," "estimates," "aims," "believes,"

"hopes," "potential", "scheduled" or similar words. Examples of such statements include, but are

not limited to, statements relating to the C-Guardians U.S. IDE clinical trial, including 30-day results from such trial and that such

results will be available to presented as a late-breaking clinical trial at VIVA23, as well as the timing and outcome of any subsequent

results, PMA or potential launch. Forward-looking statements are not guarantees of future performance, are based on certain assumptions

and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot

be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking

statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring

losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of

our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern;

our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult

to obtain and could dilute out stockholders' ownership interests; market acceptance of our products; an inability to secure and

maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets;

our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and

maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single

manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary;

the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology

is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially

greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution

and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability

to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research

and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient

or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain

intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation,

in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions,

exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance

with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair

our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with

respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that

may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange

Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security

holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation

to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Padala, Managing Director